CD38 and autoimmune thrombocytopenic purpura: Preclinical studies revealed potent pathogenic CD38+ cell-killing activity comparable with daratumumab.23 CM313 monotherapy in patients with relapsed/refractory MM (RRMM) showed a tolerable and manageable safety profile as well as promising efficacy.24 In patients with immune thrombocytopenia (ITP), CM313 maintained long-term efficacy with mainly low-grade toxic effects, supporting the therapeutic potential of CM313 in autoimmune diseases.25